Method for treating obesity
AssigneeDuke University
InventorsKishore M. Gadde, K. Ranga R. Krishnan
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
Claims11
A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant wherein said anticonvulsant is of formula (III):
- wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group —CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant according to formula (III) in amounts such that said reduction is effected, where formula (III) is:
- wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group —CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
A composition comprising at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant of formula (III):
- wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group —CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof, in an amount sufficient to effect said treatment.
Dependencies are inferred from the claim text.